Critical success factors for tomorrow’s cellular immunotherapies

Cell & Gene Therapy Insights 2021; 7(11), 1551–1557

10.18609/cgti.2021.208

Published: 13 December 2021
Interview
Bernd Schmidt

Bernd Schmidt serves as Vice President, Product Delivery at Quell Therapeutics and has 20 years of industry experience in the pharmaceutical sector, covering a broad range of innovative medicines at different stages in development and post launch. He joined Quell from GSK where he served as MPD Leader with overall accountability for the CMC development, governance and end to end supply chain of a portfolio of medicines (small molecules and cell & gene therapies) covering pre-clinical to late-phase development as well as commercial supply, incl. interactions with regulatory bodies. Prior to that he was the Technical Director and a member of the site leadership team of one of GSK’s main manufacturing facilities in the UK. Before re-joining GSK in 2012 he held roles of increasing responsibility in process and product development at AstraZeneca.